Literature DB >> 9484829

TP53 intron 6 polymorphism and the risk of ovarian and breast cancer.

D Mavridou, R Gornall, I G Campbell, D M Eccles.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9484829      PMCID： PMC2149940          DOI： 10.1038/bjc.1998.108

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  5 in total

1.  p53 polymorphism in ovarian and bladder cancer.

Authors:  J M Lancaster; H A Brownlee; R W Wiseman; J Taylor
Journal:  Lancet       Date:  1995-07-15       Impact factor: 79.321

2.  p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer.

Authors:  I B Runnebaum; X W Tong; R König; H Zhao; K Körner; E N Atkinson; R Kreienberg; D G Kieback; H ] Hong Z [corrected to Zhao
Journal:  Lancet       Date:  1995-04-15       Impact factor: 79.321

3.  p53 polymorphism in ovarian and breast cancer.

Authors:  I G Campbell; D M Eccles; B Dunn; M Davis; V Leake
Journal:  Lancet       Date:  1996-02-10       Impact factor: 79.321

4.  A novel germ line p53 mutation in intron 6 in diverse childhood malignancies.

Authors:  S Avigad; D Barel; O Blau; A Malka; M Zoldan; C Mor; M Fogel; I J Cohen; B Stark; Y Goshen; J Stein; R Zaizov
Journal:  Oncogene       Date:  1997-04-03       Impact factor: 9.867

5.  A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility.

Authors:  S Peller; Y Kopilova; S Slutzki; A Halevy; K Kvitko; V Rotter
Journal:  DNA Cell Biol       Date:  1995-12       Impact factor: 3.311
  5 in total
  9 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15.

Authors:  José Luis Soto Martínez; Carmen M Cabrera Morales; Sabio Serrano Ortega; Miguel Angel López-Nevot
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

3.  Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.

Authors:  Joellen M Schildkraut; Ellen L Goode; Merlise A Clyde; Edwin S Iversen; Patricia G Moorman; Andrew Berchuck; Jeffrey R Marks; Jolanta Lissowska; Louise Brinton; Beata Peplonska; Julie M Cunningham; Robert A Vierkant; David N Rider; Georgia Chenevix-Trench; Penelope M Webb; Jonathan Beesley; Xiaoqing Chen; Catherine Phelan; Rebecca Sutphen; Thomas A Sellers; Leigh Pearce; Anna H Wu; David Van Den Berg; David Conti; Christopher K Elund; Rebecca Anderson; Marc T Goodman; Galina Lurie; Michael E Carney; Pamela J Thompson; Simon A Gayther; Susan J Ramus; Ian Jacobs; Susanne Krüger Kjaer; Estrid Hogdall; Jan Blaakaer; Claus Hogdall; Douglas F Easton; Honglin Song; Paul D P Pharoah; Alice S Whittemore; Valerie McGuire; Lydia Quaye; Hoda Anton-Culver; Argyrios Ziogas; Kathryn L Terry; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger; Brian Calingaert; Stephen Chanock; Mark Sherman; Montserrat Garcia-Closas
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

4.  Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Authors:  Patricia Rodrigues; Jessica Furriol; Eduardo Tormo; Sandra Ballester; Ana Lluch; Pilar Eroles
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

5.  Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.

Authors:  José Luis Soto; Carmen M Cabrera; Salvio Serrano; Miguel Angel López-Nevot
Journal:  BMC Cancer       Date:  2005-04-08       Impact factor: 4.430

6.  Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.

Authors:  S Wang-Gohrke; W Weikel; H Risch; D Vesprini; J Abrahamson; C Lerman; A Godwin; R Moslehi; O Olipade; J S Brunet; E Stickeler; D G Kieback; R Kreienberg; B Weber; S A Narod; I B Runnebaum
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

Review 7.  Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.

Authors:  Roman Hrstka; Philip J Coates; Borivoj Vojtesek
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

8.  Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women.

Authors:  Matteo Floris; Giovanna Pira; Paolo Castiglia; Maria Laura Idda; Maristella Steri; Maria Rosaria De Miglio; Andrea Piana; Andrea Cossu; Antonio Azara; Caterina Arru; Giovanna Deiana; Carlo Putzu; Valeria Sanna; Ciriaco Carru; Antonello Serra; Marco Bisail; Maria Rosaria Muroni
Journal:  Oncol Lett       Date:  2022-08-08       Impact factor: 3.111

9.  TP53 Gene Polymorphisms and Occupational Skin Cancer Risks for Workers of Glass Fiber Manufacture.

Authors:  Guzel F Mukhammadiyeva; Denis O Karimov; Akhat B Bakirov; Liliya K Karimova
Journal:  Iran J Public Health       Date:  2017-11       Impact factor: 1.429
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.